No Detail Found!

Reversal Agents for Oral Anticoagulant Rivaroxaban.

Author(s)
Tanzeela Abdul Fattah Department of Chemistry Quaid-i-Azam University (QAU), Islamabad, Pakistan
Aamer Saeed Department of Chemistry Quaid-i-Azam University (QAU), Islamabad, Pakistan
Fayaz Ali Larik Department of Chemistry Quaid-i-Azam University (QAU), Islamabad, Pakistan
Pervaiz Ali Channar Department of Chemistry Quaid-i-Azam University (QAU), Islamabad, Pakistan
Abstract
Summary: The oral factor Xa inhibitor rivaroxaban has shown a favorable wellbeing and efficacy profile as compared to the well known anticoagulant drug warfarin for the prevention and treatment of thromboembolic disorders. But treatment with this anticoagulant causes an increased bleeding risk. Bleeding complications can be managed by reversal agents to keep the patient hemodynamically stable until the effect of rivaroxaban weans off. This review highlighted the pharmacological characteristics of various reversal agents including Prothrombin complex concentrate, Activated Prothrombin complex concentrate, Recombinant factor VIIa, Andexanet alfa, and Ciraparantag used in the treatment of laboratory parameters prothrombin time (PT) and clotting time (CT) for the reversal of rivaroxaban. Specific antidotes are under development which will assist the clinical administration of severe bleeding events and emergency surgery or life-threatening bleeding. Reversal agents of apixaban have also been highlighted briefly in this manuscript.
Publication Details
Page(s) 974-983
DOI DOI not available
Published Journal: Journal of Chemical Society of Pakistan, Volume: 40, Issue: 5, Year: 2018

Request the full text from PASTIC

References
S.Roehrig,A.Straub,J.Pohlmann,T.Lampe,J.Pernerstorfer,K.-H. Schlemmer , P.,Reinemer and E.,Perzborn,-, 2005.-yl} methyl) thiophene-2- carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor,J. Med 48 3 -
J.Aalbers, 2011.FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery: drug trends in cardiology,CVJA. 22 -
Fox , J. P.,Piccini , D.,Wojdyla , R. C.,Becker , J. L.,Halperin , C. C.,Nessel , J. F.,Paolini , G. J.,Hankey , K. W.,Mahaffey , M.R.,Patel, 2011.Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment,Eur. Heart. J. 32 2387 -2394
A.Straub,T.Lampe,J.Pohlmann,S.Röhrig,E.Perzborn,Y.Miao,D. M.Sarasohn,R.Parameswaran,S.Stefanik,P.Samedy,J.Wills,S.Harnicar, 2017.Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study,J. Thromb Thrombolysis 43 166 -171
B.Eriksson,L.Borris,O.Dahl,S.Haas,A.Kakkar,L.Kwong,F.Misselwitz,A.Turpie, 2009.-a novel, oral, direct factor xa inhibitor-for prevention of venous thromboembolism after major orthopaedic surgery: overview of three phase ii trials,Orthop. Proc. 91 -
W.Mueck,B. I.Eriksson,K. A.Bauer,L.Borris,O. E.Dahl,M.Gent,S.Haas,M. V.Huisman,A. K.Kakkar, 2008.Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery,Clin. Pharmacokinet 47 -
R.Altman,H. O.Vidal, 2011.Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective, 9 -
R.Goel,K.Srivathsan, 2012.Newer oral anticoagulant agents: a new era in medicine,Curr. Cardiol. Rev. 8 -
M. A.Miyares,K.Davis, 2012.Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient,Am. J. Health Syst. Pharm. 69 -
D.Adcock,R.Gosselin,Y.Tian,X.Lv,X.Xiao,M.Zhan,C.Liao, 2018.The selectivity and bioavailability improvement of novel oral anticoagulants: An overview,Eur. J. Med 146 299 -317
T. A.Fattah,A.Saeed,) D.Kubitza,M.Becka,W.Mueck,M.Zuehlsdorf, 2006.pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin,J. Clin. Pharmacol 46 981 -990
D.Kubitza,M.Becka,G.Wensing,B.Voith,M.Zuehlsdorf,b) L. Manchikanti , A. D.,Kaye , F. J.,Falco, 2018.Antithrombotic and antiplatelet therapy,In Essentials of Interventional Techniques in Managing Chronic Pain 53 59 -
M. R. Patel , K. W.,Mahaffey , J.,Garg , G.,Pan , D. E.,Singer , W.,Hacke , G. Breithardt, J. L.,Halperin , G. J.,Hankey and J. P.,Piccini,Mavrakanas , C. F.,Samer , S. J.,Nessim , G. Frisch, M. L.,Lipman, 2017.Apixaban pharmacokinetics at steady state in hemodialysis patients,J. Am. Soc. Nephrol., ASN 2016090980 -
C. Negrier , J.,Goudemand , Y.,Sultan , M.,Bertrand , C.,Rothschild and P.,Lauroua, 1997.Factor Eight Bypassing Activity, Thromb, 77 -
M.Crowther,M. A.Crowther, 2015.Antidotes for novel oral anticoagulants, Arterioscler Thromb Vasc Biol, 35 -
S.Heitmeier,V.Laux,A.Buchmüller,Levy , K.,Moore , M.,Neal , D.,Schneider , V.,Marcsisin , J.,Ariyawansa , J.,Weitz, 2018.Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers,J. Thromb. Haemost. 16 54 -64
M.Harwardt, 2007.Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors,W640 -
J. Dinkelaar , P.,Molenaar , M.,Ninivaggi , B.,Laat , H.,Brinkman and A.,Leyte,J.Thromb, 2013.In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban, 11 -
M. Levi , K.,Moore , C.,Castillejos , D.,Kubitza , S.,Berkowitz , S.,Goldhaber , M.,Raghoebar , M.,Patel , J.,Weitz and J. Levy, 2014.Comparison of threeand four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers,J. Thromb. Haemost. 12 -
E. S.Eerenberg,P. W.Kamphuisen,M. K.Sijpkens,J. C.Meijers,H. R.Buller,M.Levi, 2011.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate, 124 -
Godier , A.,Miclot , B. Le,Bonniec , M.,Durand , A. M.,Fischer , J.,Emmerich , C.,Marchand-Leroux , T.,Lecompte,C. M. Samama,J. ASA., 2012.Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model, 116 -
F.Dentali,C.Marchesi,M. G.Pierfranceschi,M.Crowther,D.Garcia,E.Hylek,D. M.Witt,N. P.Clark,A.Squizzato,D.Imberti, 2011.Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists, Thromb, 106 -
Romualdi , E.,Rancan , S.,Siragusa and W.,Ageno, 2010.Managing bleeding complications in patients treated with the old and the new anticoagulants,Curr. Pharm. Des. 16 -
R.Marlu,E.Hodaj,A,J. L.Crackowski,G.Pernod, 2012.Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban, 108 -
J. C.Keenan,C. T.Morton,D. J.Dries, 2014.Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates,BioMed Res. Int. -
K.Devreese,W.Wijns,I.Combes,M. F.Hoylaerts, 2007.Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis,Thromb. Haemost. 98 -
M. Ninivaggi , R.,Apitz-Castro , Y.,Dargaud , B. de Laat, H. C.,Hemker and T.,Lindhout, 2012.Wholeblood thrombin generation monitored with a calibrated automated thrombogram-based assay,Clin. Chem 58 -
M. Levi , T.,Moore , C.,Castillejos , S.,Berkowitz , D.,Kubitza , S.,Goldhaber , J.,Weitz and J. Levy,, 2013.Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban, 11 -
N. S.Key,C.Negrier, 2007.Coagulation factor concentrates: past, present, and future, The Lancet, 370 -
Gruber , U. M.,Marzec , U.,Buetehorn , S. R.,Hanson, 2008.Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates,Practice., 2 -
G.Escolar,V.Fernandez-Gallego,J. C.Reverter,V. V.Sanz,P.Molina,I.Lopez-Vilchez,M.Diaz-Ricart,A. M.Galan, 2013.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood, PloS one, 8 -
Ehrlich , M.,Henzl and E.,Gomperts, 2002.Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events, 8 -
Gruber , U. Marzec, U.,Buetehorn , S.,Hanson, 2009.Reversal of the antihaemostatic effects of rivaroxaban by activated factor VII and activated prothrombin complex in primates, Haematol, 181 -
W. Zhou , S.,Schwarting , S.,Illanes , A.,Liesz , M.,Middelhoff , M.,Zorn , M.,Bendszus , S.,Heiland , J. Van Ryn,R.Veltkamp, 2011.Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran, 42 -
M. K. Körber , E.,Langer , S.,Ziemer , E.,Perzborn , C.,Gericke and C. v.,Heymann, 2014.Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study,Clin. Appl 20 -
F. R.DeGuzman,S. J.Hollenbach,M. J.Karbarz,K.Abe,G.Lee,P.Luan,A.Hutchaleelaha,M.Inagaki and P. B. Conley, 2013.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,Nat. Med 19 -
K.Ghadimi,K. E.Dombrowski,J. H.Levy,I. H.Welsby, 2016.Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation,Expert Rev. Hematol. 9 -
S. J.Hollenbach,S.Tan,G.Lee,H.Athiwat,M.Inagaki,U.Sinha, 2012.PRT064445 but not recombinant Fviia reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model, Blood, 120 -
M. Vandana , K.,Michael , L.,Genmin , P. B.,Conley , H.,Stanley , J.,Castillo , A.,Hutchaleelaha , M.,Karbarz , J. P.,Lin and L.,Barron, 2013.A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors, 122 -
B.Laulicht,S.Bakhru,C.Lee,C.Baker,X.Jiang,E.Mathiowitz,J.Costin,S.Steiner, 2012.Small molecule antidote for anticoagulants,A11395 126 -
S.Hodin,J.Lanoiselée,J.Escal,S.Accassat,T.Basset,L.Bertoletti,P.Mismetti,X.Delavenne, 2016.,Effect of Activated Charcoal on Rivaroxaban Complex Absorption, Clin. Pharmacokinet 56 -
W.Ageno,A. S.Gallus,A.Wittkowsky,M.Crowther,E. M.Hylek,G.Palareti, 2012.Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines, Chest J, 141 -
A,-C. Martin , B. Le,Bonniec,A.-M. Fischer , C.,Marchand-Leroux , P.,Gaussem,C.-M. Samama , A.,Godier, 2013.Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis,Int. J. Cardiol. 168 -
F. R.DeGuzman,S. J.Hollenbach,D. R.Phillips, 2008.Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors,Am Soc Hematology -
JanssenPharmaceuticals, 2014.Xarelto prescribing information, -
X.Wang,S.Mondal,J.Wang,G.Tirucherai,D.Zhang,R. A.Boyd,C.Frost, 2014.Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects,Am. J. Cardiovasc. Drugs. 14 -
J. D. Douketis , A. C.,Spyropoulos , F. A.,Spencer , M.,Mayr , A. K.,Jaffer , M. H.,Eckman , A. S.,Dunn , R.,Kunz, 2012.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines,Chest. 141 -
D.Sankyo, 2015.,Daiichi Sankyo -
Lai , N.,Davidson , S.,Galloway , J.,Thachil, 2014.Perioperative management of patients on new oral anticoagulants,Br. J. Surg. 101 -
0

Citations

0

Downloads

58

Views